Literature DB >> 15745955

ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons.

Pablo Helguera1, Alejandra Pelsman, Gustavo Pigino, Ernst Wolvetang, Elizabeth Head, Jorge Busciglio.   

Abstract

Down's syndrome (DS) is characterized by mental retardation and development of Alzheimer's disease (AD). Oxidative stress and mitochondrial dysfunction are both related to neurodegeneration in DS. Several genes in chromosome 21 have been linked to neuronal death, including the transcription factor ets-2. Cortical cultures derived from normal and DS fetal brains were used to study the role of ets-2 in DS neuronal degeneration. ets-2 was expressed in normal human cortical neurons (HCNs) and was markedly upregulated by oxidative stress. When overexpressed in normal HCNs, ets-2 induced a stereotyped sequence of apoptotic changes leading to neuronal death. DS HCNs exhibit intracellular oxidative stress and increased apoptosis after the first week in culture (Busciglio and Yankner, 1995). ets-2 levels were increased in DS HCNs, and, between 7 and 14 d in vitro, DS HCNs showed increased bax, cytoplasmic translocation of cytochrome c and apoptosis inducing factor, and active caspases 3 and 7, consistent with activation of an apoptotic mitochondrial death pathway. Degeneration of DS neurons was reduced by dominant-negative ets-2, suggesting that increased ets-2 expression promotes DS neuronal apoptosis. In the human brain, ets-2 expression was found in neurons and astrocytes. Strong ets-2 immunoreactivity was observed in DS/AD and sporadic AD brains associated with degenerative markers such as bax, intracellular Abeta, and hyperphosphorylated tau. Thus, in DS/AD and sporadic AD brains, converging pathological mechanisms leading to chronic oxidative stress and ets-2 upregulation in susceptible neurons may result in increased vulnerability by promoting the activation of a mitochondrial-dependent proapoptotic pathway of cell death.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15745955      PMCID: PMC6726094          DOI: 10.1523/JNEUROSCI.5107-04.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  33 in total

1.  Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.

Authors:  Sarah E Lee; Monica Duran-Martinez; Sabina Khantsis; Diana W Bianchi; Faycal Guedj
Journal:  Trends Mol Med       Date:  2019-11-07       Impact factor: 11.951

2.  Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation.

Authors:  Ira T Lott; Eric Doran; Vinh Q Nguyen; Anne Tournay; Elizabeth Head; Daniel L Gillen
Journal:  Am J Med Genet A       Date:  2011-07-07       Impact factor: 2.802

3.  Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Antonella Tramutola; Alessandra Giorgi; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2014-03-25       Impact factor: 7.376

Review 4.  Antioxidants in Down syndrome.

Authors:  Ira T Lott
Journal:  Biochim Biophys Acta       Date:  2011-12-21

5.  Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype.

Authors:  Antonella Tramutola; Gilda Pupo; Fabio Di Domenico; Eugenio Barone; Andrea Arena; Chiara Lanzillotta; Diede Brokeaart; Carla Blarzino; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

6.  Activation of Ets-2 by oxidative stress induces Bcl-xL expression and accounts for glial survival in amyotrophic lateral sclerosis.

Authors:  Junghee Lee; Mari Kannagi; Robert J Ferrante; Neil W Kowall; Hoon Ryu
Journal:  FASEB J       Date:  2009-01-29       Impact factor: 5.191

Review 7.  Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology.

Authors:  Antonella Tramutola; Fabio Di Domenico; Eugenio Barone; Andrea Arena; Alessandra Giorgi; Laura di Francesco; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Antioxid Redox Signal       Date:  2016-10-26       Impact factor: 8.401

8.  Down syndrome fibroblasts and mouse Prep1-overexpressing cells display increased sensitivity to genotoxic stress.

Authors:  Nicola Micali; Elena Longobardi; Giorgio Iotti; Carmelo Ferrai; Laura Castagnaro; Mario Ricciardi; Francesco Blasi; Massimo P Crippa
Journal:  Nucleic Acids Res       Date:  2010-01-27       Impact factor: 16.971

9.  Deficits in human trisomy 21 iPSCs and neurons.

Authors:  Jason P Weick; Dustie L Held; George F Bonadurer; Matthew E Doers; Yan Liu; Chelsie Maguire; Aaron Clark; Joshua A Knackert; Katharine Molinarolo; Michael Musser; Lin Yao; Yingnan Yin; Jianfeng Lu; Xiaoqing Zhang; Su-Chun Zhang; Anita Bhattacharyya
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

10.  Adaptive downregulation of mitochondrial function in down syndrome.

Authors:  Pablo Helguera; Jaqueline Seiglie; Jose Rodriguez; Michael Hanna; Gustavo Helguera; Jorge Busciglio
Journal:  Cell Metab       Date:  2013-01-08       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.